Avadel Pharmaceuticals Highlights Upcoming Investor Events

Author: Logan Wright Updated: 08-29-2025 08:16 AM

Avadel Pharmaceuticals Announces Participation in Investor Conferences

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company committed to revolutionizing medications, has revealed that members of its management team will engage in several notable investor conferences soon. These events highlight their ongoing mission to enhance the lives of patients through innovative therapies.

Details of Investor Conferences

Here are the key dates and details of the upcoming conferences:

Wells Fargo Healthcare Conference

The first event on the calendar is the Wells Fargo Healthcare Conference, where Avadel will host a fireside chat on a Friday, discussing pertinent topics in the healthcare sector. This conference promises to be an enlightening experience for those interested in the biopharmaceutical industry.

Morgan Stanley Annual Global Healthcare Conference

Following the Wells Fargo event, Avadel will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. During this session, management will share insights into the company's innovative solutions for patients in need.

H.C. Wainwright Annual Global Investment Conference

Shortly after, Avadel will take the stage at the H.C. Wainwright 27th Annual Global Investment Conference, which will feature another engaging fireside chat. Here, they will spotlight their key achievements and future goals in addressing patient needs effectively.

Live Webcast Information

For those unable to attend these conferences in person, Avadel Pharmaceuticals will host live webcasts of the discussions through their Investor Relations website. Archived recordings will also be available for 90 days after each event, ensuring that stakeholders and potential investors can access the valuable information shared during these presentations.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals is dedicated to developing transformative medicines that improve patient life quality. The company is known for its innovative approach to drug development, with a particular focus on addressing unmet medical needs. Its flagship product, LUMRYZ™, was significantly recognized by the U.S. Food and Drug Administration (FDA) as the first and only once-at-bedtime oxybate approved for treating cataplexy or excessive daytime sleepiness in older patients with narcolepsy.

Contact Information for Investors and Media

Avadel Pharmaceuticals encourages stakeholders to reach out for any investment-related inquiries. Investor contact details include:

Austin Murtagh
Precision AQ
Email: Austin.murtagh@precisionaq.com
Phone: (212) 698-8696

For media inquiries, interested parties can contact:

Alyssa Ramirez
Real Chemistry
Email: aramirez@realchemistry.com

Frequently Asked Questions

1. What is Avadel Pharmaceuticals focused on?

Avadel Pharmaceuticals focuses on developing innovative medications that transform the lives of patients. Their products aim to address unmet medical needs effectively.

2. When will Avadel present at the Wells Fargo Healthcare Conference?

Avadel will participate in the Wells Fargo Healthcare Conference on a specified Friday. The exact time and details will be shared via their investor website.

3. How can I watch the investor conference webcasts?

The live webcasts can be accessed through Avadel's Investor Relations website, with recordings available afterward for 90 days.

4. What is LUMRYZ™?

LUMRYZ™ is Avadel's commercial product, the first once-at-bedtime oxybate approved for narcolepsy treatment in patients ages seven and older.

5. Who can I contact for investor relations?

For investor inquiries, you can contact Austin Murtagh at Precision AQ via email at Austin.murtagh@precisionaq.com.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.